Compare BioNTech SE - ADR (BNTX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Linde PLC — how do they compare? BioNTech SE - ADR trades at $90.03 (market cap $22.86B), while Linde PLC trades at $514.54 (market cap $241.59B). The key difference: Linde PLC is far larger — about 10.6× BioNTech SE - ADR's market cap, and Linde PLC pays a 1.22% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | LIN | |
|---|---|---|
Market Cap | $22.86B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $546.64 |
52-Week Low | $83.89 | $389.38 |
Enterprise Value | $6.53B | $263.95B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Linde (LIN) trades at $524.06, down 1.08% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust profitability margins including a 20.44% net income margin. Analyst consensus is strongly bullish with a $560 price target, supported by positive cash flow trends and a recent dividend declaration.
Outlook remains positive due to steady revenue growth, high return on equity of 18.49%, and institutional confidence. Risks include elevated valuation multiples like a P/E of 34.65 and rising debt-to-asset ratio, which could pressure shares if earnings growth slows. The stock presents a quality holding for growth-oriented investors mindful of valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
